Agile Therapeutics, Inc. (AGRX)

Market Cap	7.72M
Revenue (ttm)	8.40M
Net Income (ttm)	-67.01M
Shares Out	37.00M
EPS (ttm)	-26.16
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	321,028
Open	0.19
Previous Close	0.19
Day's Range	0.182 - 0.192
52-Week Range	0.183 - 27.6
Beta	1.15
Analysts	Buy
Price Target	3.06 (+1,520.8%)
Earnings Date	Nov 7, 2022

About AGRX

Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen ...

• Industry: Pharmaceuticals
• IPO Date: May 23, 2014
• CEO: Alfred Altomari
• Employees: 30
• Stock Exchange: NASDAQ
• Ticker Symbol: AGRX

Financial Performance

In 2021, AGRX's revenue was $4.10 million, an increase of 447.53% compared to the previous year's $749,000. Losses were -$74.89 million, 44.4% more than in 2020.

Analyst Forecast

According to 8 analysts, the average rating for AGRX stock is "Buy." The 12-month stock price forecast is 3.06, which is an increase of 1,520.76% from the latest price.

Price Target

$3.06

(1,520.76% upside)

Analyst Consensus: Buy